Skip to main content
Funded Studies

Kenneth Marek, MD

President and Senior Scientist at The Institute for Neurodegenerative Disorders

Kenneth Marek, MD, is President and senior scientist at the Institute for Neurodegenerative Disorders. Dr. Marek's major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson’s, Alzheimer’s and related neurodegenerative disorders. His specific interest is in in vivo neuroreceptor imaging biomarkers. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek is the principal investigator of several ongoing multi-center international studies, including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Associated Risk Syndrome (PARS) study.

Dr. Marek serves as a special scientific advisor to The Michael J. Fox Foundation. He has held leadership roles in several organizations focused on neurodegenerative disorders and has been the recipient of numerous grants to support his research. He was recently awarded the Robert A. Pritzker Prize for Leadership in Parkinson's Research. He also was a co-founder of Molecular NeuroImaging, LLC, and is now an employee and owner at Invicro, a company providing discovery and clinical neuroimaging research services. Dr. Marek earned his medical degree from Yale University, was trained in internal medicine and neurology at the Johns Hopkins School of Medicine, and received further training as a post-doctoral fellow in neurochemistry at the Institute of Neurology, Queens Square, London.

Associated Grants

  • Radioactive Molecules for Detection of Alpha-synuclein and Amyloid-beta in the Brain


  • Bay Area Solvent Study - Symptoms (BASS-S)


  • DAT Imaging in Unaffected LRRK2 Gene Positive Subjects in a Chinese Community Cohort


  • The Parkinson's Progression Markers Initiative (PPMI)


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.